Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Moderna ceo Davos
https://www.msn.com/en-ae/money/other/innovation-coming-says-moderna-ceo/vi-AA1n4GQ6
TF and all shareholders
FT. The government unveiled plans for the Vaccine Manufacturing Innovation Centre (VMIC)
https://www.thechemicalengineer.com/news/uk-s-state-backed-vaccine-manufacturing-centre-sold/
https://www.chemistryworld.com/news/uks-non-profit-vaccine-manufacturing-centre-sold-off-before-opening/4015509.article
Agree TF
Compere and contrast https://www.theguardian.com/business/2023/jun/20/designing-a-vaccine-that-covers-all-cancers-is-hard-biotech-pioneer-lindy-durrant
Moderna see last paragraph “ blind trust “ in Moderna ?
Thanks for your kind words Almas
Please find the statement from linked in , just wondering if it’s worth sending an email
Of how he got on ? Plus the 6 month evaluation from major cell therapy bio pharmaceutical company?
Find his email address
Our Chief Financial Officer Sath Nirmalananthan will be attending the @J.P Morgan Global Healthcare Conference 2024 taking place in San Francisco, California from 8-11 January.
Get in touch via sathnirmalananthan@scancell.co.uk if you are attending and would like to hear more about our cancer vaccine programmes.
Thanks Dragon I read that article earlier and the paragraph that stood out to me was
“The Covid cash has helped the company move at pace. It hopes to launch trials for mRNA vaccines to help prevent breast, pancreatic and colon cancer this year. The company has also moved beyond its mRNA pedigree and plans to start trials for antibody treatments for other cancers. “
The sentence is :
The company has also moved beyond its mRNA pedigree and plans to start trials for antibody treatments for other cancers.
Found this on LinkedIn from Poolbeg pharma 3 months ago October/ November time
Our #CEO Jeremy Skillington, PhD attended last weeks' Singer Capital Markets 'Future of Medicine' event at the Andaz London Liverpool Street .
Jeremy presented the Poolbeg Pharma plc story, with a focus on our exciting #AI programmes & took part in an engaging panel discussion alongside healthcare industry colleagues from hVIVO, Instem, ANGLE Scancell Ltd, and Diaceutics PLC.
Thank you for hosting #POLB!
#Healthcare #ArtificialIntelligence #DrugDevelopment #FutureofMedicine
Reread the RNS from pipeline of 10 th July
This paragraph stood out, Mandeep has been in the position for 6 months as has the CFO
“ Scancell has developed a novel technology platform for producing monoclonal antibodies that recognise glycans with high specificity and affinity. The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023.”
My question did anyone ask at the AGM what happened to the 6 month evaluation?
Surely now Avidimab must be generating interest?
News should be coming £0,10-11pence share price is appalling
Hope the CFO brought his pen to JPMorgan and Mandeed is working her magic!
Melanocyte Protein Pmel Market Size And Forecast
Report ID : 205321 | Published : January 2024 | Study Period : 2021-2031 | Pages : 220+ | Format : PDF + Excel
“Product (Ae-m Vaccine, Scib-1, Vpi-121, Others”
The market size of the Melanocyte Protein Pmel Market is categorized based on Application (Glioblastoma Multiforme, Melanoma, Metastatic Melanoma) and Product (Ae-m Vaccine, Scib-1, Vpi-121, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa). The provided report presents market size and predictions for the value of Melanocyte Protein Pmel Market, measured in USD million, across the mentioned segments.
The link
https://www.marketresearchintellect.com/product/melanocyte-protein-pmel-market-size-and-forecast/?utm_source=Pulse&utm_medium=016
Marcusl2: post is also good
Understood. I think the big goal for iScib+ is to work on everyone unlike Scib-1 which only works on 40% of patients. That and the Pharmajet delivery system should attract the big boys.
Trinity Delta
Preclinical work suggests that clinical benefits (in performance, efficacy, and administration) of iSCIB1+ are such a significant advance over SCIB1
The ImmunoBody therapeutic vaccine is one of Scancell’s four platforms, with the Moditope vaccine expected to deliver top-line Modi-1 CPI combination results during 2024 and the antibody platforms, GlyMab (anti-glycan mAbs) and AvidiMab, likely to see out-licencing deals too. Our Scancell rNPV valuation is £300.1m, or 36.7p/share.
The person who drafted the report posted this Today at 4.30 pm on the other board
Agree fully SCIB1 already is “trailblazing “
sci102: My issue isn't w avidimab, it's that we shouldn't put too much weight on iSCBI1+ in the short term. This is because we don't know how the new epitopes are going to work exactly and if further changes will be necessary. This is both from the point of view of safety (that's why the regulator asked for more data) and efficacy in the expanded population. If all goes smoothly, grest. But if it needs more work, that's not a disaster either. SCIB1 already has great value potential for this company and investors. It is more important to secure a partnership and it can happen with or without the current version of iSCIB1+ performing as expected.
Ruck
I have taken plenty of rubbishy criticism from some posters .
Whilst I acknowledge and accept your apology. Please be mindful of what you post. This paragraph was wrong and misleading . Why do this ? “ happy clapper “ phrase comes out when “maybe” influencer is trying to discredit certain positive posters and placing uncertainty in the company?
Sorry, it is extremely impolite to tell someone to "move on" simply because you disagree with their view. If your confidence is so low as to be so sensitive to negativity, I suggest you filter everyone except fellow happy clappers.
Telling someone to sell is also wrong. Anyone is free to buy, hold, sell as they see fit and everyone is entitled to an opinion “
Ruck
???
it was DRAGON who stated in the following post
“ RE: End of January Interim Report10 Jan 2024 19:04
Matt, it appears your expectations were not met. I suggest you sell and move on. Tired of your constant moaning”
"I am delighted that NICE have approved the novel immunotherapy combination of nivolumab-relatlimab as a treatment option for patients with advanced melanoma, potentially enabling more
patients to benefit from treatment."
Susanna Daniels, CEO Melanoma
https://www.nice.org.uk/guidance/gid-ta10581/documents/html-content-7
https://melanomafocus.org/melanoma-patient-treatment-guide/melanoma-treatment/immunotherapy-treatment/
https://www.nice.org.uk/guidance/gid-ta10581/documents/674
Https://melanomafocus.org/support/meetings-and-events/melanoma-patient-conference-2024/
itinerary not totally confirmed hope they have Lindy .
The share option for JMC and another director was 19 p both Lindy and JMC bought in recently at 11p
Only way is up !
No one can afford to wait
I
Think Seth is a good call after all he has a a degree in pharmacology?
All three subjects will present students with a challenging, technical course, that requires a great level of research and dedication. Pharmacologists, toxicologists, and pharmacists are all contributing to the care of patients through medicine, so the level of training is extremely high.
Sorry about my typos etc a reminder of the CFO credentials, from RNS "Commenting on his appointment as Chief Financial Officer, Sath Nirmalananthan said: I am excited to
be joining Scancell at such a pivotal time. With the Phase 2 single arm SCOPE trial progressing and initialtopline data readouts expected this year and Modi-1 next year, the Company is positioned with highly valuablescience and near-term inflection points that should deliver value to our shareholders. I look forward to working
with Lindy and the wider team and am excited by the potential of what can be achieved.” :
Sath Nirmalananthan is an experienced finance professional with over 15 years experience across healthcare
in FTSE and NASDAQ listed companies, investment banking and audit. Before joining Scancell, Sath was
Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health
sciences company. Prior to that, Sath worked at Reckitt where he was Finance Director for Group Reporting
and subsequently for eCommerce in Reckitt’s Health Division. Sath has also held senior positions at BTG plc,
a specialty pharmaceutical company, including Director of Group Reporting and Director of FP&A of
interventional oncology. Earlier in his career, he was an equity research analyst in the healthcare team at
Nomura and prior to that an auditor at KPMG. Sath earned a BSc in Pharmacology from King’s College,
London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath is also a Non-Executive
member of the audit committee at The Institute of Cancer Research (ICR).
Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: We are excited to have Sath join
us as Chief Financial Officer. His financial acumen and extensive track record of building value in emerging
biopharmaceutical companies will benefit Scancell in our next stage of evolution. I look forward to working with
him closely as we continue to focus the clinical development of our two lead cancer vaccine assets, SCIB1
and Modi-1, whilst continuing to leverage the potential of our proprietary antibody platform through additional
licensing and revenue generating opportunities. We are very grateful for Keith s excellent financial guidance
which has been invaluable to Scancell s success to date and are pleased that he will continue as
Morning , I suspected Scancell would be at the conference for the filling reasons
1. The festive message stating 2023 milestones
2. The Stiffel buy rates
3. the time frame being early 2024 for data
4. JPC statement at the AGM
5. the fund raise to ensure money is there for the pipeline Scancell wish to focus on , can imagine the confidence in the data , sorry no deal we have enough money ,
6, number of patients on the scope trial easier to recruit as clinician s keen
7. LD comments after her keynote speech about what Moderna person said
8. Moderna in new year media overdrive to get as much publicity as possible
9. the Liverpool Head and neck Symposium , and the slides questioning whether personalised vaccines were a way forward ?
10. last year 2022 AGM Lindy said not much media coverage , because when the news hits its Going to be BIG
11, the introduction at the AGM was " leading Global Immunology " or something like that ?
12. Downplayed the connection with Texas Biomed
13. new healthcare funds on board
14. Red mile continued support and share uptake and connection the JP Morgan and also the conference is on their home turf ,
15 prof Lindy Durrant and Scancell have done an outstanding job , quietly beavering away , tight lipped , IP patents in place , Patients in clinic , money in the bank , and a strong healthcare focused management team and a Chairman who is focused and bought shares
finally the finishing paragraph
To close the year, we were pleased to announce a successful oversubscribed and upsized fundraise of £11.9 million and would like to thank our new and existing investors for their support.
Finally, we would also like to thank the whole Scancell team for their continued efforts and hard work during 2023. Now, with a bolstered leadership team, a strong cash position to fund our current strategy and with further key data inflection points from both the SCOPE and ModiFY trial anticipated, 2024 looks to be another exciting year.
good luck to Seth and the entire Scancell team , including the Patients on trial and the Patience its needed to be "invited to the 2024 JP Morgan healthcare event "
RNS Monday morning would be lovely
IHope the latest data is released for the scope trial.modi and Covidity is released next week to coincide , which will be most interesting and indeed Moderna will have a few issues